An interactive representation of electrostimulation electrodes or vectors can be provided, such as for configuring combinations of electrostimulation electrodes. In an example, electrodes or test parameters can be presented graphically or in a table. A user interface can be configured to receive user-input designating electrode combinations or vectors for test or for use in programming an implantable or ambulatory medical device. The interface can be used to indicate suggested electrode combinations or vectors in response to a first selection of an electrode. Tests can be performed on electrode combinations and vectors, and the results of the tests can be presented to a user using the interactive representation. In an example, test results can be analyzed by a processor and optionally used to program an implantable or ambulatory medical device.

An introducing device for locating a tissue region and deploying an electrode is shown and described. The introducing device may include an outer sheath. An inner sheath may be disposed within the outer sheath. The inner sheath may be configured to engage an implantable electrode. In an example, the inner sheath may comprise a stimulation probe having an uninsulated portion at or near a distal end of the delivery sheath. The outer sheath may be coupled to a power source or stimulation signal generating circuitry at a proximal end. A clinician may control application of the stimulation signal to a tissue region via the outer sheath.

Systems and methods are disclosed for conducting spinal cord stimulation or other neurostimulation and sensing evoked compound action potential (ECAP) signals. The sensed signals may be processed to isolate ECAP features from noise and/or interfering signals. The isolated ECAP features may be used to control neurostimulation therapy for the patient and/or guide an implant procedure.

In an example, the disclosure describes a system with a lead having a proximal end and a distal end and an elongated lead body. The lead has one or more electrodes. A fixation member is located on the elongated lead body and is configured to secure the lead to tissue within a patient. The fixation member is located on the lead so the fixation member is closer to the proximal end than the one or more electrodes of the lead. A trialing adaptor receives the proximal end of the lead and is removable when a trialing period is completed. A sheath encloses at least a portion of the lead and covers the fixation member. The sheath is configured to remain in place over the lead during the trialing period.

Systems and methods for providing a trial neurostimulation to a patient for assessing suitability of a permanently implanted neurostimulation are provided herein. In one aspect, a trial neurostimulation system includes an EPG affixation device that secures the EPG to the patient when connected to a lead extending through a percutaneous incision to a target tissue location, while allowing for ready removal of the EPG for charging or bathing. In another aspect, the system includes an EPG provided with a multi-purpose connector receptacle through which the the EPG can deliver neurostimulation therapy to an implanted lead or the EPG can be charged. In yet another aspect, the EPG can include a multi-purpose connector receptacle that is alternatingly connectable with a plurality of differing connector to facilitate differing types of therapies with one or more neurostimulation devices, ground patches or various other devices, such as charging or testing devices.

Cochlear implant systems can include a signal processor, an implantable battery and/or communication module, and a plurality of conductors coupling the implantable battery and/or communication module and the signal processor. The implantable battery and/or communication module can communicate data and deliver electrical power to the signal processor via the plurality of conductors. The implantable battery and/or communication module can be configured to perform characterization process to determine one or more characteristics of one or more such conductors. Characterization processes can include determining an impedance between two conductors as a function of frequency, determining whether a conductor is intact, and determining an impedance of a given conductor. Some characterization processes include grounding one or more conductors.

The disclosure is directed to rendering visual representations of VOAs by manipulating vertices of a three-dimensional (3-D) mesh structure. In one example, a processing circuitry of a computing device may receive a 3-D mesh structure having adjustable vertices. The processing circuitry may adjust the vertices to generate an adjusted shape of the 3-D mesh structure according to an intersection between activated tissue and non-activated tissue defined by one or more stimulation parameter values.

Techniques are disclosed for determining, by an extracardiovascular implantable cardioverter defibrillator (ICD) implanted in a patient, whether one or more test therapy signals generated by another medical device implanted in the patient is detected. In response to detecting the one or more test therapy signals, the extracardiovascular ICD provides an indication that the extracardiovascular ICD has detected the one or more test therapy signals. In some examples, the indication is an audible tone provided to a clinician. In some examples, the other medical device is an intracardiac cardiac pacing device, and the one or more test therapy signals comprises a plurality of anti-tachycardia pacing (ATP) pulses.

Systems and methods for providing a trial neurostimulation to a patient for assessing suitability of a permanently implanted neurostimulation are provided herein. In one aspect, a trial neurostimulation system includes an EPG patch adhered to a skin surface of a patient and connected to a lead extending through a percutaneous incision to a target tissue location. The EPG may be a modified version of the IPG used in the permanent system, the EPG may be smaller and/or lighter than the corresponding IPG device. The EPG and a lead extension may be sealed to allow improved patient mobility and reduced risk of infection. The EPG may be compatible with wireless systems used to control and monitor the IPG such that operation and control of the EPG is substantially the same in each system to allow seemless conversion to the permanently implanted system.

In various embodiments, the present system allows for custom definition of waveforms and waveform segments for neurotherapy. Such custom definition is achieved by using a waveform composer with a user interface that makes it possible for the user to perform the custom definition of potentially very complex patterns of neurostimulation waveforms by creating and editing graphical representations of relatively simple individual building blocks for each of the patterns.